Retatrutide (also known as LY3437943) is an investigational medication developed by Eli Lilly that activates three key metabolic receptors : GLP-1 (glucagon-like peptide-1): reduces appetite and improves blood sugar control GIP (glucose-dependent insulinotropic polypeptide): enhances insulin response Glucagon receptor: increases energy expenditure and fat metabolism This triple-hormone weight loss drug approach creates a balanced effect, suppressing hunger and increasing calorie burn, something earlier GLP-1 medications couldnt fully achieve
doi: 10.1016/j.tem.2020.02.006 133 LudwigDSEbbelingCB
Goldman Sachs ran the numbers: if 30mn Americans take these drugs, GDP could rise by 0.4%
Notably, these benefits were independent of weight loss, underscoring the primary neurophysiological rather than metabolic mechanism of action [161]
(2022) addressed it by characterizing the receptor-residence-time and signaling-bias properties of retatrutide at each receptor, which together produce a pharmacology profile different from any combination of the individual single-agonist parents
This introduces another level for physicians to target both hunger and body size
